☆ 4.7 Letter

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

Xiaofei Zhu et al.

Summary: This study aimed to evaluate the efficacy of SBRT plus pembrolizumab and trametinib in patients with postoperative locally recurrent pancreatic cancer. Among 198 patients, the median overall survival was significantly longer in the SBRT plus pembrolizumab and trametinib group compared to the SBRT plus gemcitabine group. The most common adverse effects were mild to moderate in severity.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Pancreatic Adenocarcinoma, Version 2.2021

Margaret A. Tempero et al.

Summary: Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with a major challenge being advanced disease at diagnosis. While survival rates have not significantly changed, newer treatments, including targeted therapies, offer hope for patients. The manuscript focuses on systemic therapy approaches for locally advanced and metastatic disease.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Cancer statistics, 2020

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Philip A. Philip et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Review Oncology

Safety of combining radiotherapy with immune-checkpoint inhibition

William L. Hwang et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Review Gastroenterology & Hepatology

Therapeutic developments in pancreatic cancer: current and future perspectives

John P. Neoptolemos et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)

Add to Collection

Review Oncology

Radiotherapy combination opportunities leveraging immunity for the next oncology practice

Fernanda G. Herrera et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2017)

Add to Collection

Article Oncology

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

M. Aglietta et al.

ANNALS OF ONCOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Review Oncology

Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer

Rupal Ramakrishnan et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)

Add to Collection

Article Oncology

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

Patrick J. Loehrer et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies

Florence Huguet et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.